Colorectal cancer

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced rectal cancer often receive chemotherapy… Read More

#Cancer Research #News #Regulatory #Trending News

Colon cancer
#Colorectal cancer #Epigenetics #Juntendo University #Oncology

Study reveals how IL-26 reprogrammes colorectal cancer cells

Researchers have identified inflammatory cytokine interleukin-26 (IL-26) as a factor that acts on cancer cells and induces epigenetic reprogramming, promoting immune evasion.  While cancer cells acquire malignant traits through epigenetic remodelling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells.  … Read More

#Cancer Research #News #Trending News

Colorectal cancer
#Colorectal cancer #Oncology #Phase I trial #The Institute of Cancer Research

Targeted therapy shows promise in advanced colorectal cancer

A targeted antibody therapy combined with standard chemotherapy has shown early signs of tumour shrinkage and disease control in patients with advanced bowel cancer.  This is according to new Phase I clinical trial results from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation… Read More

#Cancer Research #Editor's Choice #News

Colon cancer
#Colorectal cancer #European Commission #Pierre Fabre Laboratories

EC approves metastatic colorectal cancer combination regimen 

The European Commission (EC) has approved a combination therapy for the treatment of metastatic colorectal cancer.  Braftovi (encorafenib) has been approved in combination with cetuximab and FOLOX for the first-time treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).  The approval is based on the results from the Phase III BREAKWATER trial, which… Read More

#News #Regulatory

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

Tumour microenvironment
#Cancer research #Cervical cancer #Colorectal cancer #Head and neck cancer

Drug could reduce tumours by 55%, results show 

An experimental drug could shrink tumours by up to 55%, results show.  GRWD5769, developed by biotech company Greywolf Therapeutics, is a first-in-class oral small molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), an enzyme that regulates tumour antigen presentation on MHC-I.  The drug works by… Read More

#Cancer Research #News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Colorectal cancer
#Cancer research #Colorectal cancer #Genetic profiling

Genetic pattern key to colorectal cancer, research shows 

A genetic pattern could explain how colorectal cancer develops, new research suggests.  Findings from ChristianaCare’s Helen F Graham Cancer Center & Research Institute identified a developmental genetic pattern that helps explain how colorectal cancer develops, why it becomes aggressive and how long patients are likely to survive.  The study, published… Read More

#Cancer Research #News

Colorectal cancer
#Clinical trial #Colorectal cancer #Prostate cancer

CuraCell doses first patient with TIL therapy 

Immunotherapy company CuraCell has dosed the first patients with its treatment for metastatic colorectal and metastatic prostate cancer.  CC-38 is novel autologous Tumour-Infiltrating Lymphocyte (TIL) therapy, currently being evaluated in Phase I/IIa trial. Up to 16 patients with Stage IV colorectal and prostate cancer will be enrolled in the trial, which will assess… Read More

#News

Human liver
#Clinical trial #Colorectal cancer #Liver disease

HepaRegeniX completes Phase Ib trial for liver regeneration drug 

Biotech company HepaRegeniX has completed a Phase Ib study evaluating a treatment for liver regeneration in patients undergoing minor liver resection.  Five patients in the clinical trial were treated with HRX-215 for a period of 28 days after a minor liver resection due to liver metastases originating from colorectal cancer. … Read More

#News

#Artificial intelligence (AI) #Colorectal cancer #KRAS #Oncology #Oxford Drug Design

Oxford Drug Design validates cancer therapeutic mechanism

AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More

#Cancer Research #News

X-ray showing colon cancer
#Bowel cancer #Colorectal cancer #Gene mutation #Oncology #University of Delaware

Researchers find common mutation sparks colon tumour growth

A team of researchers from ChristianaCare and the University of Delaware in the US has uncovered that a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal process, causing immature cells to build up, tissue structure to break down and early tumours to form. … Read More

#Cancer Research #Editor's Choice #News

Colorectal cancer
#Colorectal cancer #Gene mutation #Tumour biology

Gene mutation accelerates tumour growth in colorectal cancer 

A common gene mutation could be the cause of tumours forming in colorectal cancer patients, a new study suggests.  A team of researchers from ChristianaCare and the University of Delaware uncovered how a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal… Read More

#Cancer Research #News

Colorectal cancer cells
#Clinical trial #Colorectal cancer #Larkspur Biosciences

First volunteers dosed in colorectal cancer trial 

Biotechnology company Larkspur Biosciences has dosed the first volunteers in the Phase I study of its treatment for microsatellite stable (MSS), colorectal cancer (CRC) and other solid tumours.  LRK-4189 is an oral, first-in-class targeted protein degrader of the lipid kinase PIP4K2C. The drug triggers multiple killing mechanisms… Read More

#News